Grade @ or @ adverse events occurred more frequently in individuals in the ombrabulin group than in those in the placebo group and included neutropenia ( @ -LSB- @ % -RSB- in the ombrabulin group vs @ -LSB- @ % -RSB- in the placebo group ) and thrombocytopenia ( @ -LSB- @ % -RSB- vs six -LSB- @ % -RSB- for placebo ) .